Here, we evaluated the therapeutic potential of antibodies (Abs) focusing on cholinergic receptor nicotinic beta 2 subunit (CHRNB2) in gastric cancer. To examine the results of these Abs on malignant phenotypes in vitro and in mouse xenograft fashions, we generated gene knockouts by way of genome enhancing, carried out RNA interference-mediated knockdown of gene expression, and ectopically expressed CHRNB2 in gastric cancer cells. The results of anti-CHRNB2 Abs on the proliferation of cancer cells had been evaluated each in vitro and in vivo. We decided the results of Chrnb2 deficiency on mice and the medical significance of CHRNB2 expression in gastric cancer medical specimens.
Knockdown of CHRNB2 attenuated gastric cancer cell proliferation, whereas compelled overexpression of CHRNB2 elevated cell proliferation. Knockout of CHRNB2 considerably influenced cell survival and capabilities related with metastasis. The results of polyclonal Abs focusing on the C- and N-termini of CHRNB2 guided the improvement of anti-CHRNB2 monoclonal Abs that inhibited the development of gastric cancer cells in vitro and in vivo. Pathway evaluation revealed that CHRNB2 interfered with signaling by way of the PI3K-AKT and JAK-STAT pathways. Chrnb2-deficient mice exhibited regular replica, organ capabilities, and motor capabilities. CHRNB2 regulates a number of oncological phenotypes related with metastasis, and blockade of CHRNB2 expression utilizing particular Abs exhibits promise for controlling metastasis in gastric cancer.
About 25% of sufferers with IgA nephropathy (IgAN) progress to stage 5 persistent kidney illness (CKD) after years of evolution. Various instruments have been developed in recent times designed to foretell which of the sufferers will had poorer outcomes. The worth of circulating galactosyl-deficient IgA1 (Gd-IgA1) has been associated to a worse evolution of IgAN in a number of research. There are additionally some publications that relate greater APRIL values with a worse evolution. Recently, a new technique has been developed that enables measuring the worth of circulating Gd-IgA1 in a less complicated manner than these beforehand obtainable. The goal of this research is to investigate the affect of circulating Gd-IgA1, measured by this technique, on the development of IgAN.
Monoclonal Antibody Targeting the CD154 Cleavage Site Inhibits CD40-Dependent and -Independent Cleavage of CD154 from the Cell Surface
In addition to the membrane-bound molecule, soluble CD154 (sCD154) can also be detected at excessive ranges in the medium of activated T cells and platelets and in the serum of sufferers affected by completely different inflammatory ailments. This sCD154 is the consequence of cleavage of the full-length molecule between the glutamic acid residue at place 112 (E112) and methionine at place 113 (M113) and will be derived from the intracellular milieu and from cleavage of cell floor molecules. We have just lately reported that substitution of each E112 and M113 by alanine inhibits intracellular and CD40-induced membrane cleavage of CD154 and procures to CD154 an elevated organic operate as in contrast with cleavable CD154.

Thus, on this research, and in the intention of growing instruments inhibiting cleavage of CD154 from the cell floor, we generated a panel of anti-human CD154 mAbs. One of the derived mAbs that didn’t alter the binding of sCD154 to CD40, named on this research Clone eight mAb, completely misplaced its binding exercise in opposition to cells expressing CD154 mutated at its E112 and M113 residues. Treatment with Clone eight mAb was proven to fully abolish CD40-dependent and -independent cleavage of CD154 from the cell floor. Our research is highlighting the improvement and characterization of an modern therapeutic device succesful of inhibiting the launch/cleavage of CD154 from cells and thus sustaining its availability on the cell floor and the excessive in all probability of growing its efficiency as an activator of CD40-induced responses.
In this quasi-experimental pre-/postimplementation research, we estimated the effectiveness of MAb remedy inside 7 days of symptom onset in high-risk ambulatory adults with COVID-19. The main consequence was a composite of emergency division visits or hospitalizations inside 14 days of optimistic check. Secondary outcomes included adversarial occasions and 14-day mortality. The common remedy impact in the handled for MAb remedy was estimated utilizing inverse chance of remedy weighting and the affect of MAb implementation utilizing propensity-weighted interrupted time sequence evaluation.
Electrostatic Spray Drying for Monoclonal Antibody Formulation
This research explored the feasibility of electrostatic spray drying for producing a monoclonal antibody (mAb) powder formulation at decrease drying temperatures than typical spray drying and its impact on protein stability. A mAb formulation was dried by both typical spray drying or electrostatic spray drying with cost (ESD). The protein powders had been then characterised utilizing solid-state Fourier remodel infrared spectroscopy (ssFTIR), differential scanning calorimetry (DSC), dimension exclusion chromatography (SEC), and solid-state hydrogen/deuterium alternate with mass spectrometry (ssHDX-MS).
Particle characterizations reminiscent of BET floor space, particle dimension distribution, and particle morphology had been additionally carried out. Conventional spray drying of the mAb formulation at the inlet temperature of 70°C didn’t generate dry powders as a consequence of poor drying effectivity; electrostatic spray drying at the similar temperature at 5kV enabled the formation of powder formulation with passable moisture contents. Deconvoluted peak areas of deuterated samples from the ssHDX-MS research confirmed a good correlation with the loss of the monomeric peak space measured by dimension exclusion chromatography in the 90-day accelerated stability research carried out at 40°C.
DyLight®594 Conjugated Goat Anti-mouse IgG (H+L) |
BA1141-0.5 |
BosterBio |
0.5ml |
EUR 242.4 |
DyLight®594 Conjugated Goat Anti-mouse IgG (H+L) |
BA1141-1 |
BosterBio |
1ml |
EUR 400.8 |
Donkey anti Chicken IgY (H + L) (Alexa Fluor 594) |
43R-ID056AF |
Fitzgerald |
500 ug |
EUR 411.6 |
Description: Donkey anti Chicken IgY secondary antibody (H + L) (Alexa Fluor 594) |
Rabbit anti Chicken IgY (H + L) (Alexa Fluor 594) |
43R-IR016AF |
Fitzgerald |
1 mg |
EUR 337.2 |
Description: Rabbit anti Chicken IgY (H + L) secondary antibody (Alexa Fluor 594) |
DyLight®594 Conjugated Goat Anti-rabbit IgG (H+L) |
BA1142-0.5 |
BosterBio |
0.5ml |
EUR 242.4 |
DyLight®594 Conjugated Goat Anti-rabbit IgG (H+L) |
BA1142-1 |
BosterBio |
1ml |
EUR 400.8 |
Donkey Anti-Rabbit IgG (H+L), Alexa Fluor® 488 Conjugated |
Ab8032-001 |
GenDepot |
0.5mg |
EUR 522 |
iFluor™ 594 goat anti-mouse IgG (H+L) |
16468 |
AAT Bioquest |
200 ug |
EUR 138 |
|
iFluor™ 594 goat anti-mouse IgG (H+L) |
16741 |
AAT Bioquest |
1 mg |
EUR 211.2 |
|
Goat Anti-Mouse IgG (H+L) Antibody (DyLight 594) |
20-abx007449 |
Abbexa |
|
|
|
iFluor® 594 Styramide *Superior Replacement for Alexa Fluor 594 tyramide* |
45035 |
AAT Bioquest |
100 Slides |
EUR 334 |
Goat anti-Mouse IgG SecondaryAntibody (peroxidase conjugated) |
E0L3032-1 |
EnoGene |
500ul |
EUR 153.6 |
Goat anti Mouse IgG |
41R-1058 |
Fitzgerald |
2 mg |
EUR 178.8 |
Description: Goat anti Mouse IgG secondary antibody |
Goat anti Mouse IgG |
41-GM25 |
Fitzgerald |
20 mg |
EUR 220.8 |
Description: Goat anti Mouse IgG secondary antibody |
Goat anti Mouse IgG |
40-GM25S |
Fitzgerald |
100 ml |
EUR 159.6 |
Description: Goat anti Mouse IgG secondary antibody |
Goat anti Mouse IgG |
40-S8301G000-S4 |
Fitzgerald |
10 ml |
EUR 159.6 |
Description: Goat anti Mouse IgG secondary antibody |
Goat anti Mouse IgG |
20-B9015G000-S0 |
Fitzgerald |
10 ml |
EUR 159.6 |
Description: Goat anti Mouse IgG antibody |
Goat anti Mouse IgG |
20-S8301G000-V0 |
Fitzgerald |
10 ml |
EUR 159.6 |
Description: Goat anti Mouse IgG antibody |
Goat Anti Mouse IgG |
E61I00501 |
EnoGene |
100ug |
EUR 411.6 |
Goat Anti-mouse IgG |
STJ15100178 |
St John's Laboratory |
250 µg |
EUR 339.6 |
Description: Biotinylated goat anti-mouse IgG enables detection of mouse IgG in enzyme immunoassays such as indirect ELISA. |
AF594-streptavidin conjugate [Streptavidin, Alexa Fluor™ 594 Conjugate] |
16892 |
AAT Bioquest |
1 mg |
EUR 211.2 |
|
AF594 Phalloidin [equivalent to Alexa Fluor® 594 phalloidin] |
23158 |
AAT Bioquest |
300 Tests |
EUR 367.2 |
|
Polyclonal Goat anti-GST α-form |
GST-ANTI-1 |
Detroit R&D |
50 uL |
EUR 336 |
Polyclonal Goat anti-GST μ-form |
GST-ANTI-2 |
Detroit R&D |
50 uL |
EUR 336 |
Polyclonal Goat anti-GST p-form |
GST-ANTI-3 |
Detroit R&D |
50 uL |
EUR 336 |
iFluor™ 594 goat anti-rabbit IgG (H+L) |
16628 |
AAT Bioquest |
200 ug |
EUR 138 |
|
iFluor™ 594 goat anti-rabbit IgG (H+L) |
16806 |
AAT Bioquest |
1 mg |
EUR 211.2 |
|
Rabbit Anti-Goat IgG (H+L) Antibody (DyLight 594) |
20-abx007407 |
Abbexa |
|
|
|
Goat Anti-Rat IgG (H+L) Antibody (DyLight 594) |
20-abx007419 |
Abbexa |
|
|
|
Goat Anti-Rabbit IgG (H+L) Antibody (DyLight 594) |
20-abx007433 |
Abbexa |
|
|
|
iFluor™ 594 goat anti-mouse IgG (H+L) *Cross Adsorbed* |
16548 |
AAT Bioquest |
200 ug |
EUR 158.4 |
|
iFluor™ 594 goat anti-mouse IgG (H+L) *Cross Adsorbed* |
16780 |
AAT Bioquest |
1 mg |
EUR 262.8 |
|
XFD594 Anti-mouse CD19 Antibody *1D3, XFD594 Same Structure to Alexa Fluor™ 594* |
10194160 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-mouse CD19 Antibody *1D3, XFD594 Same Structure to Alexa Fluor™ 594* |
10194161 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-mouse CD197 Antibody *4B12, XFD594 Same Structure to Alexa Fluor™ 594* |
11970160 |
AAT Bioquest |
100 tests |
EUR 547 |
XFD594 Anti-mouse CD197 Antibody *4B12, XFD594 Same Structure to Alexa Fluor™ 594* |
11970161 |
AAT Bioquest |
500 tests |
EUR 2051 |
Goat Immunoglobulin G (IgG) ELISA Kit |
DLR-IgG-g-48T |
DL Develop |
48T |
EUR 556.8 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Goat Immunoglobulin G (IgG) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Goat Immunoglobulin G (IgG) ELISA Kit |
DLR-IgG-g-96T |
DL Develop |
96T |
EUR 721.2 |
|
Description: A competitive inhibition quantitative ELISA assay kit for detection of Goat Immunoglobulin G (IgG) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Goat Immunoglobulin G (IgG) ELISA Kit |
RDR-IgG-g-48Tests |
Reddot Biotech |
48 Tests |
EUR 578.4 |
Goat Immunoglobulin G (IgG) ELISA Kit |
RDR-IgG-g-96Tests |
Reddot Biotech |
96 Tests |
EUR 800.4 |
Goat anti Mouse IgG (H + L) (Agarose Conjugated) |
43R-IG044AS |
Fitzgerald |
20 mg |
EUR 585.6 |
Description: Goat anti Mouse IgG (H + L) secondary antibody (Agarose Conjugated) |
HRP-conjugated Goat Anti-Mouse IgG Heavy Chain |
AS064 |
Abclonal |
100 ul |
EUR 182.4 |
Goat anti-Mouse IgG(H+L), Biotin Conjugated |
E16SPB101-100 |
EnoGene |
100Tests |
EUR 411.6 |
Goat anti-Mouse IgG(H+L), Biotin Conjugated |
E16SPB101-1000 |
EnoGene |
1000Tests |
EUR 294 |
Goat anti-Mouse IgG(H+L), Biotin Conjugated |
E16SPB101-500 |
EnoGene |
500Tests |
EUR 200.4 |
Goat anti-Mouse IgG(H+L), FITC Conjugated |
E16SPF101-050 |
EnoGene |
50Tests |
EUR 286.8 |
Goat anti-Mouse IgG(H+L), FITC Conjugated |
E16SPF101-100 |
EnoGene |
100Tests |
EUR 411.6 |
Goat anti-Mouse IgG(H+L), FITC Conjugated |
E16SPF101-100U |
EnoGene |
100μg |
EUR 286.8 |
Goat anti-Mouse IgG(H+L), FITC Conjugated |
E16SPF101-500U |
EnoGene |
500μg |
EUR 411.6 |
Goat anti-Mouse IgG(H+L) ,HRPO Conjugated |
E16SPH101-100 |
EnoGene |
100μl |
EUR 286.8 |
Goat anti-Mouse IgG(H+L) ,HRPO Conjugated |
E16SPH101-1000 |
EnoGene |
1000μl |
EUR 520.8 |
Goat anti-Mouse IgG(H+L) ,HRPO Conjugated |
E16SPH101-500 |
EnoGene |
500μl |
EUR 411.6 |
Goat anti-Mouse IgG(H+L), PE Conjugated |
E16SPP101-020 |
EnoGene |
20Tests |
EUR 286.8 |
Goat anti-Mouse IgG(H+L), PE Conjugated |
E16SPP101-050 |
EnoGene |
50Tests |
EUR 286.8 |
Goat anti-Mouse IgG(H+L), PE Conjugated |
E16SPP101-100U |
EnoGene |
100ug |
EUR 286.8 |
Goat anti-Mouse IgG(H+L), PE Conjugated |
E16SPP101-500U |
EnoGene |
500ug |
EUR 411.6 |
Goat Anti-Mouse IgG Secondary Antibody AF790 Conjugated |
L30310 |
SAB |
0.5 ml |
EUR 151.2 |
Goat Anti-Mouse IgG Secondary Antibody Cy3 Conjugated |
L30311 |
SAB |
1.0 ml |
EUR 134.4 |
Goat Anti-Mouse IgG Secondary Antibody FITC Conjugated |
L30313 |
SAB |
1.0 ml |
EUR 116.4 |
Goat Anti-Mouse IgG Secondary Antibody APC Conjugated |
L30316 |
SAB |
0.5 ml |
EUR 229.2 |
Goat Anti-Mouse IgG Secondary Antibody PE Conjugated |
L30317 |
SAB |
1.0 ml |
EUR 229.2 |
Goat Anti-Mouse IgG Secondary Antibody PerCP Conjugated |
L30318 |
SAB |
0.5 ml |
EUR 229.2 |
Goat Anti-Mouse IgG Secondary Antibody HRP Conjugated |
L3032 |
SAB |
1.0 ml |
EUR 134.4 |
Goat Anti-Mouse IgG Secondary Antibody AP Conjugated |
L3033 |
SAB |
1.0 ml |
EUR 142.8 |
Goat Anti-Mouse IgG Secondary Antibody Biotin Conjugated |
L3034 |
SAB |
1.0 ml |
EUR 124.8 |
Goat Anti-Mouse IgG Secondary Antibody AMCA Conjugated |
L3035 |
SAB |
1.0 ml |
EUR 116.4 |
Goat Anti-Mouse IgG Secondary Antibody AF488 Conjugated |
L3036 |
SAB |
1.0 ml |
EUR 134.4 |
Goat Anti-Mouse IgG Secondary Antibody AF594 Conjugated |
L3037 |
SAB |
1.0 ml |
EUR 134.4 |
Goat Anti-Mouse IgG Secondary Antibody AF647 Conjugated |
L3038 |
SAB |
1.0 ml |
EUR 134.4 |
Goat Anti-Mouse IgG Secondary Antibody AF680 Conjugated |
L3039 |
SAB |
0.5 ml |
EUR 151.2 |
Goat Anti-Mouse IgG (H+L) Fluor594-conjugated |
S0005 |
Affbiotech |
200ul |
EUR 540 |
Goat Anti-Mouse IgG (H+L) FITC -conjugated |
S0007 |
Affbiotech |
200ul |
EUR 540 |
Goat Anti-Mouse IgG (H+L) CY3-conjugated |
S0012 |
Affbiotech |
200ul |
EUR 420 |
Goat Anti-Mouse IgG (H+L) Fluor647-conjugated |
S0014 |
Affbiotech |
200ul |
EUR 420 |
Goat Anti-Mouse IgG (H+L) TRITC-conjugated |
S0016 |
Affbiotech |
200ul |
EUR 420 |
Goat Anti-Mouse IgG (H+L) Fluor488-conjugated |
S0017 |
Affbiotech |
200ul |
EUR 420 |
iFluor 594™ PSA™ Imaging Kit with Goat Anti-Mouse IgG |
45280 |
AAT Bioquest |
100 Tests |
EUR 558 |
Goat anti Mouse IgG (HRP) |
43C-CB1569 |
Fitzgerald |
1 mg |
EUR 237.6 |
Description: Goat anti Mouse IgG secondary antibody (HRP) |
Goat anti Mouse IgG (FITC) |
43R-1359 |
Fitzgerald |
2 mg |
EUR 223.2 |
Description: Goat anti Mouse IgG secondary antibody (FITC) |
Goat anti Mouse IgG (rhodamine) |
43R-1360 |
Fitzgerald |
1 mg |
EUR 165.6 |
Description: Goat anti Mouse IgG secondary antibody (rhodamine) |
Goat anti Mouse IgG + IgM |
41R-1063 |
Fitzgerald |
1 mg |
EUR 164.4 |
Description: Goat anti Mouse IgG + IgM secondary antibody |
Goat anti Mouse IgG + IgM |
41R-1064 |
Fitzgerald |
1 mg |
EUR 232.8 |
Description: Goat anti Mouse IgG + IgM secondary antibody |
Goat Anti-Mouse IgG/HRP |
E3GAM001 |
EnoGene |
200ul |
EUR 489.6 |
Goat Anti Mouse IgG -Biotin |
E61I00502 |
EnoGene |
1mg |
EUR 598.8 |
Goat Anti Mouse IgG-HRP |
E61I00503 |
EnoGene |
1mg |
EUR 598.8 |
Goat Anti Mouse IgG-FITC |
E61I00504 |
EnoGene |
1mg |
EUR 733.2 |
Goat Anti-Mouse IgG -HRP |
LF-SA8001 |
Abfrontier |
0.5 ml |
EUR 157.2 |
Description: Goat polyclonal to mouse IgG |
Goat Anti-Mouse IgG -HRP |
LF-SA8001A |
Abfrontier |
1.0 ml |
EUR 230.4 |
Description: Goat polyclonal to mouse IgG |
Goat Anti-Mouse IgG-TRITC |
LF-SA8001TR |
Abfrontier |
1.0 mg |
EUR 344.4 |
Description: Goat polyclonal to mouse IgG |
Goat Anti-Mouse IgG (Fc) |
GAMG80Fc-0100 |
Equitech |
100ml |
EUR 485.16 |
|
Goat Anti-Mouse IgG (Fc) |
GAMG80Fc-0500 |
Equitech |
500ml |
EUR 848.64 |
|
488 Goat-anti-Mouse IgG |
GT26000 |
Neuromics |
1 mg |
EUR 450 |
546 Goat-anti-Mouse IgG |
GT26003 |
Neuromics |
1 mg |
EUR 450 |
642 Goat-anti-Mouse IgG |
GT26005 |
Neuromics |
1 mg |
EUR 450 |
Goat Anti-mouse IgG-ALP |
STJ15100031 |
St John's Laboratory |
1 ml |
EUR 420 |
Description: This ALP-conjugate enables detection of mouse IgG in enzyme immunoassays such as indirect ELISA and Western blot. |
Rabbit Anti-Rat IgG (H+L)-Alexa 488 Fluor conjugate (adsorbed with human IgG) |
50336 |
Alpha Diagnostics |
0.5 ml |
EUR 270 |
XFD594 Anti-mouse CD105 Antibody *MJ7/18, XFD594 Same Structure to Alexa Fluor™ 594* |
11050160 |
AAT Bioquest |
100 tests |
EUR 547 |
XFD594 Anti-mouse CD105 Antibody *MJ7/18, XFD594 Same Structure to Alexa Fluor™ 594* |
11050161 |
AAT Bioquest |
500 tests |
EUR 2051 |
XFD594 Anti-mouse CD106 Antibody *429 (MVCAM.A), XFD594 Same Structure to Alexa Fluor™ 594* |
11060160 |
AAT Bioquest |
100 tests |
EUR 547 |
XFD594 Anti-mouse CD106 Antibody *429 (MVCAM.A), XFD594 Same Structure to Alexa Fluor™ 594* |
11060161 |
AAT Bioquest |
500 tests |
EUR 2051 |
XFD594 Anti-mouse CD26 Antibody *H194-112, XFD594 Same Structure to Alexa Fluor™ 594* |
10260170 |
AAT Bioquest |
100 tests |
EUR 547 |
XFD594 Anti-mouse CD26 Antibody *H194-112, XFD594 Same Structure to Alexa Fluor™ 594* |
10260171 |
AAT Bioquest |
500 tests |
EUR 2051 |
XFD594 Anti-human/mouse CD44 Antibody *IM7, XFD594 Same Structure to Alexa Fluor™ 594* |
10441170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human/mouse CD44 Antibody *IM7, XFD594 Same Structure to Alexa Fluor™ 594* |
10441171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-mouse CD86 Antibody *GL-1, XFD594 Same Structure to Alexa Fluor™ 594* |
10860170 |
AAT Bioquest |
100 tests |
EUR 547 |
XFD594 Anti-mouse CD86 Antibody *GL-1, XFD594 Same Structure to Alexa Fluor™ 594* |
10860171 |
AAT Bioquest |
500 tests |
EUR 2051 |
Anti-RPSA Alexa Fluor® 488 |
A4-829-C100 |
ExBio |
0.1 mg |
EUR 372 |
Anti-CD40 antibody (Alexa-fluor 488) |
STJ170000 |
St John's Laboratory |
100 µg |
EUR 471.6 |
Description: CD40 (48 to 50 kDa) is a transmembrane glycoprotein mainly expressed on the surface of B cells and also expressed on monocytes, dendritic cells, and thymic epithelium. CD40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which includes the low affinity nerve growth factor (NGF) receptor and CD95/Fas. CD40 is the receptor for CD40 ligand. CD40L (CD40L, CD154, gp39, and TRAM) belongs to the TNF gene family and is expressed more widely than CD40, predominantly on activated CD4+ T cells. Following interaction with CD40 ligand, CD40 mediates a number of major immunoregulatory functions, central to the control of thymus dependent humoral immunity and may be critical in the development of cell mediated immune responses. Other biological actions include B cell homotypic adhesion, proliferation, immunoglobulin isotype switch, and secretion. Activation of CD40 has also been shown to inhibit the growth of certain B cell lymphomas and to induce the death of transformed cells of mesenchymal or epithelial origin |
Anti-LAMP3 antibody (Alexa-fluor 488) |
STJ170004 |
St John's Laboratory |
100 µg |
EUR 471.6 |
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface. |
Anti-LAMP3 antibody (Alexa-fluor 546) |
STJ170005 |
St John's Laboratory |
100 µg |
EUR 471.6 |
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface. |
Anti-LAMP3 antibody (Alexa-fluor 647) |
STJ170006 |
St John's Laboratory |
100 µg |
EUR 471.6 |
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface. |
Anti-IL3RA antibody (Alexa-fluor 488) |
STJ170009 |
St John's Laboratory |
100 µg |
EUR 471.6 |
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
Anti-IL3RA antibody (Alexa-fluor 546) |
STJ170010 |
St John's Laboratory |
100 µg |
EUR 471.6 |
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
Anti-IL3RA antibody (Alexa-fluor 647) |
STJ170011 |
St John's Laboratory |
100 µg |
EUR 471.6 |
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
Anti-CD207 antibody (Alexa-fluor 488) |
STJ170014 |
St John's Laboratory |
100 µg |
EUR 471.6 |
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
Anti-CD207 antibody (Alexa-fluor 546) |
STJ170015 |
St John's Laboratory |
100 µg |
EUR 471.6 |
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
Anti-CD207 antibody (Alexa-fluor 647) |
STJ170016 |
St John's Laboratory |
100 µg |
EUR 471.6 |
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
Anti-IL7R antibody (Alexa-fluor 488) |
STJ170020 |
St John's Laboratory |
100 µg |
EUR 471.6 |
Description: The IL7-R consists of 2 chains, IL-7R known as CD127 and common cytokine receptor chain known as CD132. A 75 to 80kDa human IL-7 receptor has been cloned that belongs to hematopoietic cytokinereceptor super family. R34-34, raised against human leukemic pre-B cells, recognized a molecule expressed on normal B cell precursors but not on mature B cells. This antibody specifically reverted IL-7 mediated growth inhibition of leukemic BCP (normal B cells precursors) and mature T cells. IL-7R expression is dramatically influenced by cytokines and antigens. This IL-7R displays both high and low affinity for its ligand (IL-7). Inhibitory and proliferative effects of IL-7 can be mediated through the same receptor on various lineages. CD4+ memory T cells express high level of IL-7R Subsets that express it generally require it, including progenitors of T and B cells, naïve and memory T cells. (Pandrau-Garcia D et al, 1994, Blood, 83, 3613-9 Mazzucchelli R et al, Nat. Review Immunol., 2007,7, 144-54) |
Anti-IL7R antibody (Alexa-fluor 546) |
STJ170021 |
St John's Laboratory |
100 µg |
EUR 471.6 |
Description: The IL7-R consists of 2 chains, IL-7R known as CD127 and common cytokine receptor chain known as CD132. A 75 to 80kDa human IL-7 receptor has been cloned that belongs to hematopoietic cytokinereceptor super family. R34-34, raised against human leukemic pre-B cells, recognized a molecule expressed on normal B cell precursors but not on mature B cells. This antibody specifically reverted IL-7 mediated growth inhibition of leukemic BCP (normal B cells precursors) and mature T cells. IL-7R expression is dramatically influenced by cytokines and antigens. This IL-7R displays both high and low affinity for its ligand (IL-7). Inhibitory and proliferative effects of IL-7 can be mediated through the same receptor on various lineages. CD4+ memory T cells express high level of IL-7R Subsets that express it generally require it, including progenitors of T and B cells, naïve and memory T cells. (Pandrau-Garcia D et al, 1994, Blood, 83, 3613-9 Mazzucchelli R et al, Nat. Review Immunol., 2007,7, 144-54) |
Anti-IL7R antibody (Alexa-fluor 647) |
STJ170022 |
St John's Laboratory |
100 µg |
EUR 471.6 |
Description: The IL7-R consists of 2 chains, IL-7R known as CD127 and common cytokine receptor chain known as CD132. A 75 to 80kDa human IL-7 receptor has been cloned that belongs to hematopoietic cytokinereceptor super family. R34-34, raised against human leukemic pre-B cells, recognized a molecule expressed on normal B cell precursors but not on mature B cells. This antibody specifically reverted IL-7 mediated growth inhibition of leukemic BCP (normal B cells precursors) and mature T cells. IL-7R expression is dramatically influenced by cytokines and antigens. This IL-7R displays both high and low affinity for its ligand (IL-7). Inhibitory and proliferative effects of IL-7 can be mediated through the same receptor on various lineages. CD4+ memory T cells express high level of IL-7R Subsets that express it generally require it, including progenitors of T and B cells, naïve and memory T cells. (Pandrau-Garcia D et al, 1994, Blood, 83, 3613-9 Mazzucchelli R et al, Nat. Review Immunol., 2007,7, 144-54) |
Goat anti Human IgG (Fc) (Agarose Conjugated) |
43R-IG016AS |
Fitzgerald |
2 ml |
EUR 457.2 |
Description: Goat anti Human IgG secondary antibody (Fc) (Agarose Conjugated) |
Goat anti-Rabbit IgG SecondaryAntibody (peroxidase conjugated) |
E0L3012-1 |
EnoGene |
500ul |
EUR 153.6 |
Goat anti-Rabbit IgG SecondaryAntibody (peroxidase conjugated) |
E0L3012-2 |
EnoGene |
1000ul |
EUR 216 |
HRP Conjugated anti-Goat IgG SABC Kit |
SA1023 |
BosterBio |
1 kit |
EUR 182.4 |
FITC Conjugated anti-Goat IgG SABC Kit |
SA1066 |
BosterBio |
1 kit |
EUR 400.8 |
Cy3 Conjugated anti-Goat IgG SABC Kit |
SA1076 |
BosterBio |
1 kit |
EUR 426 |
HRP Conjugated anti-Goat IgG SABC Kit |
SA2003 |
BosterBio |
1 kit |
EUR 400.8 |
HRP-conjugated AffiniPure Goat Anti-Mouse IgG Light Chain |
AS062 |
Abclonal |
100 ul |
EUR 182.4 |
Mouse anti Goat IgG heavy chain-HRP Conjugated Antibody |
C48068 |
SAB |
100ul |
EUR 476.4 |
Mouse anti goat IgG lighty chain-HRP Conjugated Antibody |
C48078 |
SAB |
100ul |
EUR 476.4 |
Goat Anti-Mouse IgG Secondary Antibody Rhodamine (TRITC) Conjugated |
L30314 |
SAB |
1.0 ml |
EUR 116.4 |
Goat Anti-Mouse IgG Secondary Antibody Rhodamine (RRX) Conjugated |
L30315 |
SAB |
1.0 ml |
EUR 116.4 |
XFD594 tyramide reagent *Same Structure to Alexa Fluor™ 594 tyramide* |
11082 |
AAT Bioquest |
200 slides |
EUR 222 |
iFluor™ 594 goat anti-rabbit IgG (H+L) *Cross Adsorbed* |
16698 |
AAT Bioquest |
200 ug |
EUR 158.4 |
|
iFluor™ 594 goat anti-rabbit IgG (H+L) *Cross Adsorbed* |
16833 |
AAT Bioquest |
1 mg |
EUR 262.8 |
|
XFD594 Anti-mouse/human/rat CD47 Antibody *MIAP410, XFD594 Same Structure to Alexa Fluor™ 594* |
10473170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-mouse/human/rat CD47 Antibody *MIAP410, XFD594 Same Structure to Alexa Fluor™ 594* |
10473171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-mouse/human CD49d Antibody *PS/2, XFD594 Same Structure to Alexa Fluor™ 594* |
10490170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-mouse/human CD49d Antibody *PS/2, XFD594 Same Structure to Alexa Fluor™ 594* |
10490171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-mouse CD49 Antibody *5H10-27 (MFR5), XFD594 Same Structure to Alexa Fluor™ 594* |
10493170 |
AAT Bioquest |
100 tests |
EUR 547 |
XFD594 Anti-mouse CD49 Antibody *5H10-27 (MFR5), XFD594 Same Structure to Alexa Fluor™ 594* |
10493171 |
AAT Bioquest |
500 tests |
EUR 2051 |
XFD594 Anti-mouse/ dog CD80 Antibody *16-10A1, XFD594 Same Structure to Alexa Fluor™ 594* |
10800170 |
AAT Bioquest |
100 tests |
EUR 547 |
XFD594 Anti-mouse/ dog CD80 Antibody *16-10A1, XFD594 Same Structure to Alexa Fluor™ 594* |
10800171 |
AAT Bioquest |
500 tests |
EUR 2051 |
XFD594 Anti-human CD47 Antibody *HI172, XFD594 Same Structure to Alexa Fluor™ 594* |
10471170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD47 Antibody *HI172, XFD594 Same Structure to Alexa Fluor™ 594* |
10471171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD52 Antibody *HI186, XFD594 Same Structure to Alexa Fluor™ 594* |
10520170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD52 Antibody *HI186, XFD594 Same Structure to Alexa Fluor™ 594* |
10520171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD53 Antibody *HI29, XFD594 Same Structure to Alexa Fluor™ 594* |
10530170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD53 Antibody *HI29, XFD594 Same Structure to Alexa Fluor™ 594* |
10530171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD53 Antibody *HI36, XFD594 Same Structure to Alexa Fluor™ 594* |
10531170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD53 Antibody *HI36, XFD594 Same Structure to Alexa Fluor™ 594* |
10531171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD55 Antibody *HI55a, XFD594 Same Structure to Alexa Fluor™ 594* |
10550170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD55 Antibody *HI55a, XFD594 Same Structure to Alexa Fluor™ 594* |
10550171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD56 Antibody *My31, XFD594 Same Structure to Alexa Fluor™ 594* |
10562160 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD56 Antibody *My31, XFD594 Same Structure to Alexa Fluor™ 594* |
10562161 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD57 Antibody *HI57a, XFD594 Same Structure to Alexa Fluor™ 594* |
10570170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD57 Antibody *HI57a, XFD594 Same Structure to Alexa Fluor™ 594* |
10570171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD58 Antibody *HI58a, XFD594 Same Structure to Alexa Fluor™ 594* |
10580170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD58 Antibody *HI58a, XFD594 Same Structure to Alexa Fluor™ 594* |
10580171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD62 Antibody *HI62E, XFD594 Same Structure to Alexa Fluor™ 594* |
10620170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD62 Antibody *HI62E, XFD594 Same Structure to Alexa Fluor™ 594* |
10620171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD62l Antibody *HI62L, XFD594 Same Structure to Alexa Fluor™ 594* |
10621170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD62l Antibody *HI62L, XFD594 Same Structure to Alexa Fluor™ 594* |
10621171 |
AAT Bioquest |
500 tests |
EUR 918 |
XFD594 Anti-human CD62p Antibody *HI62P, XFD594 Same Structure to Alexa Fluor™ 594* |
10622170 |
AAT Bioquest |
100 tests |
EUR 245 |
XFD594 Anti-human CD62p Antibody *HI62P, XFD594 Same Structure to Alexa Fluor™ 594* |
10622171 |
AAT Bioquest |
500 tests |
EUR 918 |
Low-temperature (70°C inlet temperature) drying with an electrostatic cost (5kV) led to higher protein bodily stability as in contrast with the samples spray-dried at the excessive temperature (130°C inlet temperature) with out cost. This research exhibits that electrostatic spray drying can produce strong monoclonal antibody formulation at decrease inlet temperature than conventional spray drying with higher bodily stability.